Anil Singh, MD
Pulmonary Disease · Denison, TXNPI 1275847162
Payments from drug & device makers
Across 456 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$611
- Baxter Healthcare$550
- Takeda Pharmaceuticals U.S.A., Inc.$456
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,0788%
- Food & beverage$8,60167%
- Education$3,07524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $4,258 |
| GSK | 127 | $1,759 |
| AstraZeneca | 72 | $1,732 |
| Actelion Pharmaceuticals US, Inc. | 24 | $611 |
| Baxter Healthcare | 30 | $550 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $456 |
| Sanofi | 19 | $451 |
| Mylan Specialty L.p. | 21 | $326 |
| Amgen | 16 | $279 |
| Viatris Specialty LLC | 13 | $243 |
| Regeneron Healthcare Solutions, Inc. | 9 | $240 |
| Mallinckrodt Hospital Products Inc. | 12 | $234 |
| Johnson & Johnson(3 entities) | 8 | $225 |
| Boehringer Ingelheim | 12 | $194 |
| AbbVie(2 entities) | 2 | $162 |
| Grifols USA, LLC | 8 | $138 |
| Merck | 6 | $112 |
| United Therapeutics Corporation | 5 | $103 |
| ANI Pharmaceuticals, Inc. | 5 | $102 |
| Insmed, Inc. | 5 | $91 |
| Gilead | 5 | $86 |
| Bayer | 4 | $81 |
| Verona Pharma, Inc. | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Advanced Respiratory, Inc | 2 | $37 |
| Vifor Pharma, Inc. | 1 | $26 |
| Philips North America LLC | 1 | $24 |
| Vapotherm Inc | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Harmony Biosciences LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,754 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 532 | $389,449 |
| OfevNintedanib Esylate | 16 | $208,446 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 249 | $173,379 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $40,605 |
| Spiriva RespimatTiotropium Bromide | 70 | $39,604 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 151 | $18,369 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $16,335 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $14,479 |
| EliquisApixaban | 11 | $14,382 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $10,842 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,475 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 392 | $8,142 |
| Roflumilast | 95 | $7,890 |
| Wixela InhubFluticasone Propion/Salmeterol | 51 | $7,774 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,759 | $452,977660 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $194 | $267,367118 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,732 | $187,858289 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Denison
- Sanober KableDenison$910K
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.